The importance of NF-kB pathway in myeloma

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 3 Dec 2018
Views: 1112
Dr Nizar Bahlis - University of Calgary, Calgary, Canada

Dr Nizar Bahlis speaks to ecancer at ASH 2018 about the results of the TOURMALINE-MM1 study and the use of proteasome inhibitors.

He explains that the study compares lenalidomide‑dexamethasone with a combination of lenalidomide‑dexamethasone and ixazomib in relapsed/refractory multiple myeloma patients with the combination arm superior in showing improving progression free survival.

Dr Bahlis acknowledges the importance of the NF-κB pathway and that patients with an activated non-canonical NF-κB pathway saw the best benefit from the ixazomib and lenalidomide‑dexamethasone combination.

He also discusses the use proteasome inhibitors (PIs) as a treatment for multiple myeloma patients and the benefit of PI maintenance.

This programme has been supported by an unrestricted educational grant from Takeda.